The effect of beta-blockers on the adaptive immune system in chronic heart failure

Cardiovascular Therapeutics

Volumn 27, Issue 3, 2009, Pages 181-186

  Shaw, Steven M ^a   Coppinger, Teresa ^a   Waywell, Carolyn ^a   Dunne, Louise ^a   Archer, Louise D ^a   Critchley, William R ^a   Yonan, Nizar ^a   Fildes, James E ^a   Williams, Simon G ^a  

^a WYTHENSHAWE HOSPITAL   (United Kingdom)

Author keywords

Beta blockers; Heart failure; Immune system

Indexed keywords

BISOPROLOL; CANDESARTAN; CARVEDILOL; ENALAPRIL; HLA DR ANTIGEN; LISINOPRIL; LOSARTAN; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; NEBIVOLOL; PERINDOPRIL; RAMIPRIL; VALSARTAN;

ADAPTIVE IMMUNITY; ADULT; ANTIGEN EXPRESSION; ARTICLE; BLOOD SAMPLING; CARDIAC RESYNCHRONIZATION THERAPY; COMPUTER PROGRAM; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FEMALE; FLOW CYTOMETRY; HEART EJECTION FRACTION; HEART FAILURE; HUMAN; IMMUNE SYSTEM; LYMPHOCYTE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OUTPATIENT; PATHOGENESIS; PRIORITY JOURNAL; PROSPECTIVE STUDY;

ADRENERGIC BETA-ANTAGONISTS; AGED; BENZOPYRANS; BISOPROLOL; CARBAZOLES; CHRONIC DISEASE; COHORT STUDIES; EDETIC ACID; ETHANOLAMINES; FEMALE; FLOW CYTOMETRY; HEART FAILURE; HLA-DR ANTIGENS; HUMANS; IMMUNE SYSTEM; MALE; MIDDLE AGED; PROPANOLAMINES; PROSPECTIVE STUDIES; STROKE VOLUME; T-LYMPHOCYTES, CYTOTOXIC;

EID: 68849101783     PISSN: 17555914     EISSN: 17555922     Source Type: Journal    
DOI: 10.1111/j.1755-5922.2009.00089.x     Document Type: Article

References (21)

1. The Beta-Blocker Evaluation of Survival Trial Investigators. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 2001 344 : 1659 1667.
2. Poole-Wilson PA, Swedberg K, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the carvedilol or Metoprolol European Trial (COMET): Randomised controlled trial. Lancet 2003 362 : 7 13.
3. Fukunaga T, Soejima H, Irie A, et al. Expression of interferon-gamma and interleukin-4 production in CD4+ T cells in patients with chronic heart failure. Heart Vessels 2007 22 : 178 183.
4. Fukunaga T, Soejima H, Irie A, et al. Relation between CD4+ T-cell activation and severity of chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 2007 100 : 483 488.
5. Celis R, Torre-Martinez G, Torre-Amione G. Evidence for activation of immune system in heart failure: Is there a role for anti-inflammatory therapy Curr Opin Cardiol 2008 23 : 254 260.
6. Ramasubbu K, Oliveira G, Torre-Amione G. Novel therapies for heart failure: Focus on anti-inflammatory strategies. Congest Heart Fail 2006 12 : 153 159 quiz 160-151.
7. Flather MD, Shibata MC, Coats AJ, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005 26 : 215 225.
8. Packer M, Fowler MB, Roecker EB, et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: Results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation 2002 106 : 2194 2199.
9. MERIT-HF Study Group. Effect of metoprolol CRXL in chronic heart failure. Metoprolol CRXL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999 353 : 2001 2007.
10. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II). A randomised trial. Lancet 1999 353 : 9 13.
11. Maffei A, Di Pardo A, Carangi R, et al. Nebivolol induces nitric oxide release in the heart through inducible nitric oxide synthase activation. Hypertension 2007 50 : 652 656.
12. Wolf SC, Sauter G, Preyer M, Poerner T, Kempf VA, Risler T, Brehm B. Influence of nebivolol and metoprolol on inflammatory mediators in human coronary endothelial or smooth muscle cells. Effects on neointima formation after balloon denudation in carotid arteries of rats treated with nebivolol. Cell Physiol Biochem 2007 19 : 129 136.
13. Pauschinger M, Rutschow S, Chandrasekharan K, et al. Carvedilol improves left ventricular function in murine coxsackievirus-induced acute myocarditis association with reduced myocardial interleukin-1beta and MMP-8 expression and a modulated immune response. Eur J Heart Fail 2005 7 : 444 452.
14. Baumgarth N, Roederer M. A practical approach to multicolor flow cytometry for immunophenotyping. J Immunol Methods 2000 243 : 77 97.
15. Ohtsuka T, Hamada M, Hiasa G, et al. Effect of beta-blockers on circulating levels of inflammatory and anti-inflammatory cytokines in patients with dilated cardiomyopathy. J Am Coll Cardiol 2001 37 : 412 417.
16. Mann DL, McMurray JJ, Packer M, et al. Targeted anticytokine therapy in patients with chronic heart failure: Results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 2004 109 : 1594 1602.
17. Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: Results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 2003 107 : 3133 3140.
18. Betts MR, Brenchley JM, Price DA, De Rosa SC, Douek DC, Roederer M, Koup RA. Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. J Immunol Methods 2003 281 : 65 78.
19. Varda-Bloom N, Leor J, Ohad DG, et al. Cytotoxic T lymphocytes are activated following myocardial infarction and can recognize and kill healthy myocytes in vitro. J Mol Cell Cardiol 2000 32 : 2141 2149.
20. Holzinger C, Schollhammer A, Imhof M, et al. Phenotypic patterns of mononuclear cells in dilated cardiomyopathy. Circulation 1995 92 : 2876 2885.
21. Ueno A, Murasaki K, Hagiwara N, Kasanuki H. Increases in circulating T lymphocytes expressing HLA-DR and CD40 ligand in patients with dilated cardiomyopathy. Heart Vessels 2007 22 : 316 321.